An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy

Trial Profile

An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2017

At a glance

  • Drugs ATYR 1940 (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions
  • Sponsors aTyr Pharma
  • Most Recent Events

    • 15 May 2017 Status changed from active, no longer recruiting to completed.
    • 24 Apr 2017 Top-Line results published in an aTyr Pharma media release.
    • 13 Dec 2016 Interim results published in an aTyr Pharma Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top